07/28/2004
Media Relations Contact:
Virginia Amann or Amy Beltran
Atkins + Associates for Kereos
608-274-6046 or 858-527-3489
vamann@irpr.com or abeltran@irpr.com
St. Louis, MO. – July 28, 2004 - Kereos, a biotechnology company developing targeted therapeutics and molecular imaging agents for the treatment and detection of cancer and cardiovascular disease, announced today that it has been selected as one of the “Fierce 15” for 2004 by FierceBiotech, an internationally-recognized publication for the biotech industry. Kereos was chosen as one of the top emerging biotechnology companies from more than 500 privately held firms for the company’s vision, management expertise, and overall potential to change the way disease is treated.
“Kereos’ development of nanotechnology-based targeted therapeutics and imaging agents could result in the earlier detection and more targeted treatment of two leading killers of Americans – cardiovascular disease and cancer,” said John Carroll, editor of FierceBiotech. “The Fierce 15 celebrates the spirit of innovation and aggressive development of new products, and we are pleased to honor those biotechnology companies with great potential to change the landscape of biotechnology.”
"We believe that our cancer products will enable physicians to find tumors earlier and treat them more effectively, while our lead cardiovascular products should be the first to find and treat the unstable plaque underlying most heart attacks, ” said Robert “Al” Beardsley, Ph.D., CEO of Kereos. "Kereos is honored to be chosen from among so many outstanding companies in our industry, and to be recognized for that vision and for the experienced team of professionals dedicated to realizing it.”
The Fierce 15 roster of winners is available in today’s issue of FierceBiotech and on the FierceBiotech Web site at www.fiercebiotech.com.
Kereos develops products designed to provide more effective treatment and detection of cancer and cardiovascular disease, the first of which is expected to enter clinical trials in 2005. In addition to advancing its pipeline of therapeutic and imaging candidates independently, Kereos is committed to partnering with leading pharmaceutical and imaging companies. To date, it has formed collaborations with Bristol-Myers Squibb Medical Imaging for the development and commercialization of cardiovascular disease magnetic resonance imaging (MRI) agents and with Philips Medical Systems for the development of molecular imaging systems. For more information, visit Kereos' website at www.kereos.com.
FierceBiotech is an internationally recognized email newsletter for the biotech industry. Every business day, more than 31,000 executives in over 100 countries rely on FierceBiotech for a quick, authoritative briefing on the day’s top stories. It is published by FierceMarkets, Inc. a business publishing company based in Washington D.C.
Back to Press Releases
|
